ReviewJournal of clinical and experimental hematopathology : JCEH2019
Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders.
Review in Journal of clinical and experimental hematopathology : JCEH, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 94 citations in OpenAlex.
- Methotrexate-associated Lymphoproliferative Disorder Showing Colon and Liver Lesions Difficult to Distinguish from Colon Cancer with Liver Metastases.Internal medicine (Tokyo, Japan) · 2026Article
- Concurrent cytomegalovirus iridocyclitis and vitreoretinal lymphoma in the same eye during long-term infliximab therapy: a case report.Journal of ophthalmic inflammation and infection · 2026Article
- Article
- Methotrexate-Associated Lymphoproliferative Disorder Presenting as Obstructive Jaundice Due to Pancreatic Involvement.Internal medicine (Tokyo, Japan) · 2025Article
- Development of Diffuse Large B Cell Lymphoma in a Patient with Systemic Lupus Erythematosus within Two Years after the Initiation of Anifrolumab and Mycophenolate Mofetil Treatment.Internal medicine (Tokyo, Japan) · 2025Article
- Diffuse thyroid enlargement and its regression in methotrexate-associated lymphoproliferative disorder: an ultrasonographic observation.Endocrinology, diabetes & metabolism case reports · 2025Article
- Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop.Virchows Archiv : an international journal of pathology · 2025Review
- Lymphoproliferations in People Living with HIV: Oncogenic Pathways, Diagnostic Challenges, and New Therapeutic Opportunities.Cancers · 2025Review
- Cognitive Dysfunction as an Initial Manifestation of Rheumatoid Arthritis-associated Intravascular Large B-cell Lymphoma.Internal medicine (Tokyo, Japan) · 2025Review
- A Review of the Impact of Sjögren's Syndrome and/or the Presence of Anti-Ro/SS-A Antibodies on Therapeutic Strategies for Rheumatoid Arthritis.Journal of clinical medicine · 2025Review
- Composite Lymphoma after Treatment with Infliximab for Sarcoidosis and Ankylosing Spondylitis.Internal medicine (Tokyo, Japan) · 2025Article
- Treatment of Methotrexate-Associated Lymphoproliferative Disorder With Biological Therapies.Cureus · 2025Article
- Successful Treatment of Methotrexate-associated Lymphoproliferative Disorder with the Pola-R-CHP Regimen.Internal medicine (Tokyo, Japan) · 2025Article
- Hepatic methotrexate-associated lymphoproliferative disease: a case report and literature review.Surgical case reports · 2024Article
- Other iatrogenic immunodeficiency-associated lymphoproliferative disorder presenting with multiple facial tumors.JAAD case reports · 2024Article
- Article
- Iatrogenic immunodeficiency-associated lymphoproliferative disorder presenting as small bowel perforation.BMJ case reports · 2024Article
- Hepatic and lung methotrexate-associated polymorphic lymphoproliferative disorders arising during postoperative follow-up of renal cell carcinoma: a case report.Journal of medical case reports · 2023Article
- [Other iatrogenic immunodeficiency associated lymphoproliferative diseases in children with lymphoma: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPD), a category of immunodeficiency-associated LPD according to the World Health Organization classification, is associated with immunosuppressive drugs (ISDs). Several factors, including autoimmune disease (AID) activity, Epstein-Barr virus (EBV) infection, ISD usage, and aging, influence the development of OIIA-LPD, resulting in complicated clinical courses and outcomes. Most OIIA-LPD develops in patients with rheumatoid arthritis using methotrexate (MTX-LPD). The management of MTX-LPD is based on the clinical course, i.e., with/without regression, with/without relapse/regrowth event (RRE), LPD subtype, and ISDs for AIDs after LPD development. There are three clinical courses after ISD withdrawal: regressive LPD without relapse/regrowth (R-G), regressive LPD with RRE (R/R-G), and persistent LPD (P-G). The majority of EBV+ diffuse large B-cell lymphomas are classified in R-G, whereas classic Hodgkin lymphoma is generally classified in R/R-G. Polymorphic LPD (P-LPD) in MTX-LPD develops with heterogeneous pathological features similar to monomorphic LPD. Chemotherapy for MTX-LPD is selected according to that for de novo LPD, although the strategy for aggressive P-LPD and non-specific LPD is not well established. The absolute lymphocyte count in the peripheral blood has been suggested as a candidate marker for MTX-LPD development and RRE. Several clinical issues, including correct diagnosis among overlapping clinicopathological features in MTX-LPD and clinical management of LPD by ISDs other than MTX, require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.